Latest Pharma and Biotech News
Biotechnology
24 June 2025 The US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan or Dato-DXd) to treat adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Today's issue
Refine Search
Biotechnology
Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine prevention study showed that Ajovy (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in cutting frequency, duration and severity of attacks in chronic and episodic migraine. 25 June 2025
Biotechnology
Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or chronic primary immune thrombocytopenia (ITP). 25 June 2025
Biotechnology
US biotech PTC Therapeutics’ (Nasdaq: PTCT) Sephience (sepiapterin) has been granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU). The authorization includes a broad label inclusive of all ages and disease severities. 25 June 2025
Generics
Israeli generics major Teva Pharmaceutical Industries has highlighted that Europe is experiencing increasing pressure on its medicines supply. 25 June 2025
Biotechnology
In a busy day for the US drugmaker, Kymera Therapeutics yesterday announced a licensing deal with Gilead Sciences updated on its collaboration with French pharma major Sanofi. 25 June 2025
Pharmaceutical
In a sector where regulation is tight and reputation is paramount, bold, purposeful leadership has never been more necessary, writes Alessandro Buccella of Heidrick & Struggles, in an Expert View. 25 June 2025
Pharmaceutical
Republican Senator Bill Cassidy has called for Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) to be delayed. 25 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Pharmaceutical
The UK government has unveiled a sweeping industrial strategy aimed at catapulting the country into the top tier of global life sciences economies by 2035. Positioned as one of eight growth sectors, life sciences is set to benefit from a multibillion-dollar push to streamline regulation, enhance health data infrastructure, and accelerate innovation. 25 June 2025
Biosimilars
Germany’s Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of FYB203/Ahzantive (aflibercept-mrbb), Formycon’s biosimilar to Bayer’s Eylea, concluded an exclusive license agreement with US biosimilars specialist Valorum Biologics for the commercialization of the product in the USA and Canada. 25 June 2025
Pharmaceutical
Health and Human Services Secretary Robert F Kennedy Jr came under heavy scrutiny from Democratic lawmakers during a heated budget hearing on Capitol Hill, as concerns mounted over his handling of vaccine policy, sweeping agency cuts, and what some members described as a disregard for transparency and scientific integrity. 25 June 2025
Pharmaceutical
The UK has become the first country in the world to join a new global network of health regulators focused on the safe, effective use of artificial intelligence (AI) in healthcare. 25 June 2025
Pharmaceutical
Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV infection, making the first and only FDA approved HIV pre-exposure prophylaxis (PrEP) option offering six months of protection. 25 June 2025
Pharmaceutical
BrightGene Pharmaceutical unveiled promising mid‑stage results for its investigational treatment BGM0504 at the American Diabetes Association conference, challenging established competitors in metabolic disease. 25 June 2025
Biotechnology
US biotech BioMarin Pharmaceutical has presented new five-year data from its pivotal Phase III trial of Roctavian (valoctocogene roxaparvovec), showing sustained bleed control and a stable safety profile for adults with severe hemophilia A. 25 June 2025
Pharmaceutical
Nuvalent, a US biopharma developing precisely targeted therapies for clinically-proven kinase targets in cancer, has announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). 24 June 2025
Pharmaceutical
Sciwind Biosciences has shared late-stage trial data for its injectable GLP-1 therapy, signaling Chinese firms’ intensifying bid to challenge incumbents like Eli Lilly and Novo Nordisk in the global obesity drug market. 24 June 2025
Biotechnology
Revolution Medicines, a Californian oncology specialist developing targeted therapies for RAS-addicted cancers, has partnered with Royalty Pharma on $2 billion in flexible funding to support the former company’s independent global development and commercialization strategy and operations. 24 June 2025
Biotechnology
US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported the successful outcome of a study related to atopic dermatitis. 24 June 2025
Pharmaceutical
See-sawing global tariffs, a US regulator in flux and a possible end to US drug price premia are not, apparently, enough to stymie pharmaceutical industry growth. 24 June 2025
All news
Biotechnology
Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine prevention study showed that Ajovy (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in cutting frequency, duration and severity of attacks in chronic and episodic migraine. 25 June 2025
Biotechnology
Japan’s largest drugmaker Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody, in patients with persistent or chronic primary immune thrombocytopenia (ITP). 25 June 2025
Biotechnology
US biotech PTC Therapeutics’ (Nasdaq: PTCT) Sephience (sepiapterin) has been granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU). The authorization includes a broad label inclusive of all ages and disease severities. 25 June 2025
Generics
Israeli generics major Teva Pharmaceutical Industries has highlighted that Europe is experiencing increasing pressure on its medicines supply. 25 June 2025
Biotechnology
In a busy day for the US drugmaker, Kymera Therapeutics yesterday announced a licensing deal with Gilead Sciences updated on its collaboration with French pharma major Sanofi. 25 June 2025
Pharmaceutical
In a sector where regulation is tight and reputation is paramount, bold, purposeful leadership has never been more necessary, writes Alessandro Buccella of Heidrick & Struggles, in an Expert View. 25 June 2025
Pharmaceutical
Republican Senator Bill Cassidy has called for Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) to be delayed. 25 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Pharmaceutical
The UK government has unveiled a sweeping industrial strategy aimed at catapulting the country into the top tier of global life sciences economies by 2035. Positioned as one of eight growth sectors, life sciences is set to benefit from a multibillion-dollar push to streamline regulation, enhance health data infrastructure, and accelerate innovation. 25 June 2025
Biosimilars
Germany’s Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of FYB203/Ahzantive (aflibercept-mrbb), Formycon’s biosimilar to Bayer’s Eylea, concluded an exclusive license agreement with US biosimilars specialist Valorum Biologics for the commercialization of the product in the USA and Canada. 25 June 2025
Pharmaceutical
Health and Human Services Secretary Robert F Kennedy Jr came under heavy scrutiny from Democratic lawmakers during a heated budget hearing on Capitol Hill, as concerns mounted over his handling of vaccine policy, sweeping agency cuts, and what some members described as a disregard for transparency and scientific integrity. 25 June 2025
Pharmaceutical
The UK has become the first country in the world to join a new global network of health regulators focused on the safe, effective use of artificial intelligence (AI) in healthcare. 25 June 2025
Pharmaceutical
Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV infection, making the first and only FDA approved HIV pre-exposure prophylaxis (PrEP) option offering six months of protection. 25 June 2025
Pharmaceutical
BrightGene Pharmaceutical unveiled promising mid‑stage results for its investigational treatment BGM0504 at the American Diabetes Association conference, challenging established competitors in metabolic disease. 25 June 2025
Biotechnology
US biotech BioMarin Pharmaceutical has presented new five-year data from its pivotal Phase III trial of Roctavian (valoctocogene roxaparvovec), showing sustained bleed control and a stable safety profile for adults with severe hemophilia A. 25 June 2025
Pharmaceutical
Nuvalent, a US biopharma developing precisely targeted therapies for clinically-proven kinase targets in cancer, has announced positive pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI (tyrosine kinase inhibitor) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). 24 June 2025
Pharmaceutical
Sciwind Biosciences has shared late-stage trial data for its injectable GLP-1 therapy, signaling Chinese firms’ intensifying bid to challenge incumbents like Eli Lilly and Novo Nordisk in the global obesity drug market. 24 June 2025
Biotechnology
Revolution Medicines, a Californian oncology specialist developing targeted therapies for RAS-addicted cancers, has partnered with Royalty Pharma on $2 billion in flexible funding to support the former company’s independent global development and commercialization strategy and operations. 24 June 2025
Biotechnology
US biotech Nektar Therapeutics experienced a remarkable 130% increase in its share price, which reached $21.9, as it reported the successful outcome of a study related to atopic dermatitis. 24 June 2025
Pharmaceutical
See-sawing global tariffs, a US regulator in flux and a possible end to US drug price premia are not, apparently, enough to stymie pharmaceutical industry growth. 24 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze